Mirae raises £4.1m led by Oxford Science Enterprises
This article covers Mirae, a healthtech startup, which has raised £4.1m in a growth funding round led by Oxford Science Enterprises to build an AI-driven continuous care platform for autoimmune and other complex chronic conditions. The funding is intended to support development and validation of a conversational AI system that captures patient-reported experience between visits and integrates it with clinical data to provide clinicians and patients with a continuous, actionable view of disease.
Mirae, a healthtech startup, has raised £4.1m in a growth funding round led by Oxford Science Enterprises to build an AI-driven continuous care platform for autoimmune and other complex chronic conditions. The funding will support development and validation of Mirae’s system — which captures patient-reported experience between visits and combines it with clinical data and evidence to give clinicians a continuous, actionable view of disease — a capability that could change how episodic care is delivered.
Why it matters
Autoimmune conditions such as inflammatory bowel disease are characterised by unpredictable flares, complex medication choices, and highly variable responses to treatment. Clinicians typically rely on infrequent appointments and fragmented notes, leaving much of a patient’s lived experience invisible to the care team.
Mirae’s approach aims to fill that gap by turning day-to-day patient inputs into structured, longitudinal records that clinicians can use at the point of care. If the platform performs as claimed, it could reduce decision uncertainty, speed treatment adjustments and make specialist insight more consistently available between visits. The company says it is already working with a leading US health system to access real-world data for model building and validation.
Inside the product
Mirae’s platform uses conversational AI to capture symptom reports, medication changes and daily behaviours in plain language. The system asks follow-up questions, tracks trajectories and constructs a continuous record that links to clinical context such as lab results and treatment history.
For patients, the product is presented as a low-friction way to log what matters to their care, helping them spot triggers and see how they respond to therapies. For clinicians, Mirae produces a compact, up-to-date summary of a patient’s disease trajectory so appointments can focus on assessing treatment options rather than reconstructing history from memory and fragmented notes.
The technology builds directly on research from the University of Oxford’s Computational Health Informatics Lab, led by co-founder Dr David Clifton, which has worked on modelling disease progression using large-scale longitudinal clinical data.
Who are the investors?
The £4.1m round was led by Oxford Science Enterprises. The announcement did not list other named participants.
In the announcement, Joel Schoppig, Health Tech Principal, Oxford Science Enterprises, said:
AI is moving quickly into healthcare, but much of that activity remains broad, generalized, and disconnected from the clinical decisions that determine outcomes. Its greatest impact will come from areas where decisions are complex, conditions evolve, and the cost of getting those decisions wrong is high. Mirae is building for this deeper layer of medicine, where patient context, clinical evidence, and workflow need to come together to support a higher standard of care.
The investor rationale emphasises clinical applicability: OSE frames Mirae’s work as addressing decision complexity in chronic conditions by integrating patient context with clinical evidence and workflow to influence outcomes at the point of care.
If you're researching potential backers in this space:
- Explore our list of healthtech venture capital firms in the UK
- Browse our directory of healthtech angel investors in the UK
Founder perspective
Mirae’s co-founder and CEO framed the problem in practical terms. In the announcement, Anuj Patel, co-founder and CEO of Mirae, said:
Where you live should not dictate the quality of care you receive. A lot of the variability in care and outcomes comes from the fact that clinicians are working without a full view of what has happened between visits. The limitations of AI in understanding and modeling complex disease comes from the fact that patients are living with their disease every day, but that experience rarely makes it into the clinical record in a usable way. When you combine experiential data with clinical data, you begin to understand and model disease more effectively and have a path towards true precision medicine. Every patient deserves access to world class decision-making for their care and the tools to take ownership over their condition between visits.
Patel’s comments underline the company’s twin focus: patient-facing capture of everyday experience and clinical tools that fold that experience into decision workflows.
The bigger picture
Mirae’s funding and Oxford provenance underline ongoing momentum in UK healthtech spinouts that combine academic research with applied clinical partnerships. The company’s initial focus on IBD — a condition with substantial clinical need and variable outcomes — is a common pattern: UK-founded teams often test tightly defined use cases before broadening scope across chronic disease.
The round also highlights continued transatlantic ties: Mirae’s deployment with a US health system is being used to develop and validate models on routinely collected, real-world data. That path — Oxford research to UK company to US validation partner — is increasingly common for digital health startups seeking large, diverse datasets and clinical workflows that can scale.
As regulators, payers and providers in the UK and Europe scrutinise the role of AI in care, firms that can show demonstrable clinical utility and integration into clinician workflows are likely to gain most traction. Mirae’s funding will be watched as an example of how academic insight and conversational AI can be combined to address the limits of episodic care across chronic conditions.
They've invested in Mirae
Get to know these healthtech investors
| Investors | Investment Focus | Startup Investments | Round Size | Connect |
|---|---|---|---|---|
 Oxford Science Enterprises( ) The firm focuses on investing in Life Sciences, Health Tech, and Deep Tech, prim... Oxford  | ||||
| All investors | All investor sectors | All funded startups | All funding rounds |
Click here for a full list of 7,589+ startup investors in the UK